Skip to content
OpenCapital
Get started

Mineralys Therapeutics, Inc. MLYS Q2 2025 earnings

Reported August 12, 2025 · After market close

EPS-$0.66Beat by $0.12
EPS estimate-$0.78

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.57

Financials

Q2 2025

Income statement

See full
Operating income-$46.7M-3.5%
Net income-$43.3M-5.5%
EPS (diluted)-$0.66+20.5%

Balance sheet

See full
Cash & equivalents$1.0M+940%
Total equity$313.6M+8.1%
Total assets$335.7M+5.4%

Cash flow

See full
Operating cash flow-$30.2M-0.1%
CapEx-—
Free cash flow-$30.2M-0.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$921.58M+75.4%

Returns & leverage

See full
Return on equity-63.2%+68.1pp
Current ratio15.1×+3.9×

Versus estimates

Diluted EPS

Q1 2026-$0.47Beat by $0.04Q4 2025-$0.40Beat by $0.12Q3 2025-$0.52Beat by $0.14
Q2 2025-$0.66Beat by $0.12
Q1 2025-$0.79Beat by $0.23Q4 2024-$0.98Beat by $0.02

Ask the moment Mineralys Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Mineralys Therapeutics, Inc. report Q2 2025 earnings?
Mineralys Therapeutics, Inc. (MLYS) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Mineralys Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Mineralys Therapeutics, Inc. reported eps of $-0.66 for Q2 2025.
Did Mineralys Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.78 by $0.12.
How did Mineralys Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 20.5% from $-0.83.
Where can I find Mineralys Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001933414-25-000090) directly on SEC EDGAR. The filing index links above go to sec.gov.